Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

BKM120 in Cancers With PIK3CA Activating Mutations

This study has been withdrawn prior to enrollment.
(The study has been closed due to lack of accrual)
Sponsor:
Collaborator:
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Jeffrey Engelman, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT01501604
First received: December 27, 2011
Last updated: September 16, 2015
Last verified: September 2015
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Study Completion Date: August 2013
  Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)